Katharina Sophia Volz: Bridging Stem Cell Biology and AI Drug Discovery
Katharina Sophia Volz is a distinguished German-American medical researcher and entrepreneur who has made significant strides in both regenerative medicine and biotechnology. By combining a deep foundation in stem cell biology with the power of modern computation, Volz is currently leading efforts to accelerate the discovery of treatments for complex brain diseases.
As the founder and CEO of OccamzRazor, a biotech startup operating in New York City and San Francisco, she is leveraging machine learning—a subset of artificial intelligence that allows systems to learn from data—to identify cures for brain-aging conditions, including Parkinson's disease.
Key Facts
- Founder & CEO: OccamzRazor, a biotech firm focusing on AI-driven drug discovery for brain diseases.
- Academic Milestone: First Ph.D. in stem cell biology and regenerative medicine at Stanford University, completed in a record 2.5 years.
- Scientific Breakthrough: Identified pericytes as the stem cells that form coronary arteries.
- Global Recognition: Named in MIT Technology Review's "Innovators Under 35" and Forbes "30 Under 30" (2017).
- International Influence: Trusted speaker for UNESCO and a former United Nations WED fellow.
Early Life and Academic Excellence
Born in 1987 in Ulm, Germany, and raised in nearby Erbach, Volz attended the Valckenburgschule grammar school. Her academic journey began with studies in molecular biology at the University of Graz, which eventually led her to conduct high-level research across several of the world's most prestigious institutions, including Harvard Medical School, UCLA, Ohio State University, and the Howard Hughes Medical Institute.
The Stanford Breakthrough
Volz's tenure at Stanford University was marked by unprecedented speed and discovery. In 2012, she became the first person to earn a Ph.D. in stem cell biology and regenerative medicine from the university, completing the degree in just 2.5 years. During this time, she achieved a major scientific milestone by identifying the specific stem cells responsible for forming coronary arteries. She discovered that pericytes—progenitor stem cells—transform into smooth muscle cells when blood flow increases.
Professional Career and Global Recognition
Beyond the laboratory, Volz has established herself as a global thought leader in science and innovation. Her contributions have been recognized by several international bodies and prestigious lists:
- United Nations & UNESCO: She served as a United Nations WED fellow in 2015 and is a trusted speaker for UNESCO. In 2020, she joined the first cohort of the United Nations Nexus Accelerator program.
- Innovation Awards: She was featured on the global Forbes 30 Under 30 list in 2017 and recognized as one of the top 35 under 35 innovators by MIT Technology Review.
- Scientific Community: Volz was a recurring participant at the Science Foo Camp from 2017 through 2019.
OccamzRazor: The Future of Drug Discovery
Applying her expertise in biology to the tech sector, Volz founded OccamzRazor. The company focuses on the intersection of biology and machine learning to solve the "biggest problem in science": the slow and often inefficient process of drug discovery for brain-aging diseases.
The startup's mission is to create a more efficient map for finding cures for conditions like Parkinson's. To achieve this, OccamzRazor has secured grant funding and partnerships with esteemed organizations, including the Michael J. Fox Foundation, the Sergey Brin Family Foundation, and Stanford. The venture is further supported by prominent investors such as Randy Schekman and Jeff Dean.
Summary of Professional Profile
| Category | Details |
|---|---|
| Education | Ph.D. in Stem Cell Biology & Regenerative Medicine (Stanford University) |
| Key Discovery | Pericytes as progenitors for coronary artery smooth muscle |
| Current Role | Founder and CEO of OccamzRazor |
| Specialization | AI-driven drug discovery for brain-aging diseases |
| Major Honors | MIT Innovators Under 35, Forbes 30 Under 30 |
Frequently Asked Questions
What is OccamzRazor?
OccamzRazor is a biotechnology startup founded by Katharina Sophia Volz that utilizes machine learning to discover and develop new drugs for brain-aging diseases, such as Parkinson's.
What was Katharina Volz's major discovery at Stanford?
She was the first person to identify that pericytes, a type of progenitor stem cell, turn into smooth muscle cells in response to increased blood flow to form coronary arteries.
How quickly did she complete her Ph.D.?
Katharina Volz completed her Ph.D. in stem cell biology and regenerative medicine at Stanford University in a record time of 2.5 years.
Which organizations support OccamzRazor?
The company has received grant funding or partnerships from the Michael J. Fox Foundation, the Sergey Brin Family Foundation, and Stanford, with additional support from investors Jeff Dean and Randy Schekman.
What international roles has she held?
She has been a United Nations WED fellow, a member of the United Nations Nexus Accelerator program, and a trusted speaker for UNESCO.